AU2015350128B2 - Combination therapy for treatment of resistant bacterial infections - Google Patents

Combination therapy for treatment of resistant bacterial infections Download PDF

Info

Publication number
AU2015350128B2
AU2015350128B2 AU2015350128A AU2015350128A AU2015350128B2 AU 2015350128 B2 AU2015350128 B2 AU 2015350128B2 AU 2015350128 A AU2015350128 A AU 2015350128A AU 2015350128 A AU2015350128 A AU 2015350128A AU 2015350128 B2 AU2015350128 B2 AU 2015350128B2
Authority
AU
Australia
Prior art keywords
pharmaceutically acceptable
acceptable salt
sulbactam
compound
imipenem
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2015350128A
Other languages
English (en)
Other versions
AU2015350128A1 (en
Inventor
Boudewijn Lodewijk Maria Dejonge
Thomas Francois Durand-Reville
John Mueller
Ruben Tommasi
Jeroen Cunera Verheijen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Entasis Therapeutics Ltd
Original Assignee
Entasis Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Entasis Therapeutics Ltd filed Critical Entasis Therapeutics Ltd
Publication of AU2015350128A1 publication Critical patent/AU2015350128A1/en
Application granted granted Critical
Publication of AU2015350128B2 publication Critical patent/AU2015350128B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2015350128A 2014-11-17 2015-11-17 Combination therapy for treatment of resistant bacterial infections Active AU2015350128B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462080667P 2014-11-17 2014-11-17
US62/080,667 2014-11-17
PCT/US2015/061076 WO2016081452A1 (en) 2014-11-17 2015-11-17 Combination therapy for treatment of resistant bacterial infections

Publications (2)

Publication Number Publication Date
AU2015350128A1 AU2015350128A1 (en) 2017-06-01
AU2015350128B2 true AU2015350128B2 (en) 2019-05-16

Family

ID=54704148

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015350128A Active AU2015350128B2 (en) 2014-11-17 2015-11-17 Combination therapy for treatment of resistant bacterial infections

Country Status (31)

Country Link
US (2) US9968593B2 (enExample)
EP (1) EP3221313B1 (enExample)
JP (1) JP6764862B2 (enExample)
KR (1) KR102542392B1 (enExample)
CN (1) CN107108624B (enExample)
AU (1) AU2015350128B2 (enExample)
BR (1) BR112017010132B1 (enExample)
CA (1) CA2966632C (enExample)
CY (1) CY1121384T1 (enExample)
DK (1) DK3221313T3 (enExample)
EA (1) EA033829B1 (enExample)
ES (1) ES2717776T3 (enExample)
HK (1) HK1244798B (enExample)
HR (1) HRP20190580T1 (enExample)
HU (1) HUE044061T2 (enExample)
IL (1) IL251979B (enExample)
LT (1) LT3221313T (enExample)
ME (1) ME03357B (enExample)
MX (1) MX2017006383A (enExample)
MY (1) MY196240A (enExample)
PH (1) PH12017500852B1 (enExample)
PL (1) PL3221313T3 (enExample)
PT (1) PT3221313T (enExample)
RS (1) RS58429B1 (enExample)
SG (1) SG11201703633TA (enExample)
SI (1) SI3221313T1 (enExample)
SM (1) SMT201900187T1 (enExample)
TR (1) TR201905233T4 (enExample)
TW (1) TWI690317B (enExample)
WO (1) WO2016081452A1 (enExample)
ZA (1) ZA201703245B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法
WO2017203266A1 (en) * 2016-05-25 2017-11-30 Entasis Therapeutics Limited Combination therapy for treatment of resistant bacterial infections
SG11201901658PA (en) * 2016-09-16 2019-04-29 Entasis Therapeutics Ltd Beta-lactamase inhibitor compounds
EP3301094A1 (en) * 2016-09-30 2018-04-04 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
EA037916B1 (ru) * 2017-02-08 2021-06-07 Энтасис Терапеутикс Лимитед Соединения-ингибиторы бета-лактамаз
PT3630111T (pt) 2017-05-08 2022-03-01 Entasis Therapeutics Inc Compostos e métodos de tratamento de infeções bacterianas
CN109422765B (zh) * 2017-09-05 2020-08-28 香港理工大学深圳研究院 C类β-内酰胺酶抑制剂及其制备方法和应用
AU2019233613B2 (en) * 2018-03-13 2025-02-13 Sepsia Therapeutics, S.L. Bacterial-binding peptides for treatment of infectious diseases and related inflammatory processes
CN121154634A (zh) * 2018-03-14 2025-12-19 正大天晴药业集团股份有限公司 含阿维巴坦的抗菌组合物及其用途
US11905286B2 (en) 2018-08-09 2024-02-20 Antabio Sas Diazabicyclooctanones as inhibitors of serine beta-lactamases
EP4272831A3 (en) 2018-08-09 2024-02-21 Antabio SAS Diazabicyclooctanones as inhibitors of serine beta-lactamases
CN111658642A (zh) * 2019-03-05 2020-09-15 广州新创忆药物临床研究有限公司 一种治疗耐碳青霉烯类抗生素鲍曼不动杆菌感染的组合物
TWI715397B (zh) * 2019-12-31 2021-01-01 高雄榮民總醫院 根據領先標準將同儕數據繪製為圖表的方法、電腦程式產品及電腦可讀取媒體
JP2023528560A (ja) * 2020-04-02 2023-07-05 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド ゲポチダシンを用いて淋菌感染症を治療するためのレジメン
US20250352521A1 (en) * 2021-01-20 2025-11-20 Entasis Therapeutics Limited Fixed dosage antibiotic compositions
WO2023206580A1 (en) * 2022-04-29 2023-11-02 Entasis Therapeutics Limited Durlobactam crystalline forms
WO2025239896A1 (en) * 2024-05-16 2025-11-20 Entasis Therapeutics, Inc. Treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible isolates of acinetobacter baumannii-calcoaceticus complex
CN121955228A (zh) * 2025-12-31 2026-05-01 北京大学人民医院 同时检测亚胺培南、雷利巴坦和西司他丁的方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013150296A1 (en) * 2012-04-02 2013-10-10 Astrazeneca Ab Heterobicyclic compounds as beta-lactamase inhibitors
WO2014033561A1 (en) * 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
WO2014122468A1 (en) * 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177099T1 (de) 1993-12-29 1999-03-15 Pfizer Diazabicyclische neurokinin antagonisten
FR2812635B1 (fr) * 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2835186B1 (fr) 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) * 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors
FR2914923B1 (fr) 2007-04-12 2013-06-14 Novexel Nouveaux composes heterocycliques azotes,leur preparation et leur utilisation comme medicaments antibacteriens.
JP5038509B2 (ja) * 2008-01-18 2012-10-03 メルク・シャープ・エンド・ドーム・コーポレイション β−ラクタマーゼ阻害剤
FR2930553B1 (fr) 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
EP2921559A1 (en) 2008-06-19 2015-09-23 Astra Zeneca Holding France Use of (1r,2s,5r) 1,6-diazabicyclo [3.2.1]octane-2-carboxamide, 7-oxo-6-(sulfooxy)-, monosodium salt as a diagnostic reagent for detecting serine beta-lactamases
FR2936798B1 (fr) 2008-10-03 2012-09-28 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens.
FR2936951B1 (fr) * 2008-10-10 2010-12-03 Novexel Nouvelles combinaisons de composes heterocycliques azotes antibacteriens avec d'autres composes antibacteriens et leur utilisation comme medicaments
FR2937034B1 (fr) 2008-10-10 2012-11-23 Novexel Nouveaux composes heterocycliques azotes, leur preparation et leur utilisation comme medicaments antibacteriens
FR2951171A1 (fr) 2009-10-09 2011-04-15 Novexel Nouveau sel de sodium d'un compose azabicyclique sous forme enantiomere cristallisee et nouvelles formes polymorphes et pseudopolymorphes ainsi que leur preparation
EP2768503A1 (en) * 2011-07-26 2014-08-27 Wockhardt Limited Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
CA2842777C (en) 2011-07-26 2015-12-29 Wockhardt Limited Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
BR112013028813B1 (pt) 2011-08-27 2020-10-20 Wockhardt Limited derivados de 1,6-diazabiciclo[3,2,1]octan-7-ona e composições farmacêuticas que os compreendem
CN103649088B (zh) 2011-08-30 2016-05-11 沃克哈特有限公司 1, 6- 二氮杂双环[3, 2, 1]辛- 7- 酮衍生物及其在治疗细菌感染中的用途
BR112014003476A2 (pt) 2011-09-13 2017-03-01 Wockhardt Ltd compostos contendo nitrogênio e seu uso
US8796257B2 (en) 2011-12-02 2014-08-05 Naeja Pharmaceutical Inc. Bicyclic compounds and their use as antibacterial agents and β-lactamase inhibitors
EP2814483A2 (en) * 2012-02-15 2014-12-24 Rempex Pharmaceuticals, Inc. Methods of treating bacterial infections
US8969570B2 (en) 2012-03-30 2015-03-03 Cubist Pharmaceuticals, Inc. Beta-lactamase inhibitors
TW201343645A (zh) 2012-03-30 2013-11-01 Cubist Pharm Inc １，３，４－□二唑及１，３，４－噻二唑β－內醯胺酶抑制劑
JP2015512419A (ja) 2012-03-30 2015-04-27 キュービスト ファーマシューティカルズ， インコーポレイテッド イソオキザゾールβ−ラクタマーゼ阻害剤
US8916709B2 (en) 2012-03-30 2014-12-23 Cubist Pharmaceuticals, Inc. 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors
HUE046893T2 (hu) 2012-05-30 2020-04-28 Meiji Seika Pharma Co Ltd Új ß-laktamáz inhibitor és eljárás elõállítására
ES2672100T3 (es) 2012-08-25 2018-06-12 Wockhardt Limited Derivados de 1,6-diazabiciclo[3,2,1]octano-7-ona y su uso en el tratamiento de infecciones bacterianas
WO2014141132A1 (en) * 2013-03-14 2014-09-18 Naeja Pharmaceutical Inc. NEW HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTIBACTERIAL AGENTS AND β-LACTAMASE INHIBITORS
TWI690317B (zh) 2014-11-17 2020-04-11 英商安特西醫療有限公司 用於治療抗藥性細菌感染之組合療法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013150296A1 (en) * 2012-04-02 2013-10-10 Astrazeneca Ab Heterobicyclic compounds as beta-lactamase inhibitors
WO2014033561A1 (en) * 2012-09-03 2014-03-06 Wockhardt Limited Antibacterial compositions
WO2014122468A1 (en) * 2013-02-06 2014-08-14 Astrazeneca Ab Combination therapy for the treatment of nosocomial pneumonia

Also Published As

Publication number Publication date
NZ731601A (en) 2024-02-23
TW201625234A (zh) 2016-07-16
KR102542392B1 (ko) 2023-06-09
US20180289681A1 (en) 2018-10-11
EA033829B1 (ru) 2019-11-29
US10376499B2 (en) 2019-08-13
MX2017006383A (es) 2017-08-21
AU2015350128A1 (en) 2017-06-01
DK3221313T3 (en) 2019-04-08
WO2016081452A1 (en) 2016-05-26
IL251979A0 (en) 2017-06-29
PH12017500852B1 (en) 2023-03-08
EP3221313A1 (en) 2017-09-27
TR201905233T4 (tr) 2019-05-21
CN107108624B (zh) 2020-01-07
HUE044061T2 (hu) 2019-09-30
ME03357B (me) 2019-10-20
HK1244798B (en) 2020-02-21
PL3221313T3 (pl) 2019-07-31
SI3221313T1 (sl) 2019-04-30
US20180000800A1 (en) 2018-01-04
CA2966632A1 (en) 2016-05-26
PH12017500852A1 (en) 2017-11-06
SG11201703633TA (en) 2017-06-29
JP2017533945A (ja) 2017-11-16
TWI690317B (zh) 2020-04-11
KR20170082635A (ko) 2017-07-14
BR112017010132A2 (pt) 2018-01-02
CN107108624A (zh) 2017-08-29
HRP20190580T1 (hr) 2019-05-17
IL251979B (en) 2020-10-29
ZA201703245B (en) 2019-08-28
EA201791069A1 (ru) 2017-11-30
CA2966632C (en) 2023-10-03
JP6764862B2 (ja) 2020-10-07
CY1121384T1 (el) 2020-05-29
SMT201900187T1 (it) 2019-05-10
PT3221313T (pt) 2019-04-15
EP3221313B1 (en) 2019-01-09
ES2717776T3 (es) 2019-06-25
US9968593B2 (en) 2018-05-15
RS58429B1 (sr) 2019-04-30
MY196240A (en) 2023-03-24
BR112017010132B1 (pt) 2023-02-14
LT3221313T (lt) 2019-03-25

Similar Documents

Publication Publication Date Title
US10376499B2 (en) Combination therapy for treatment of resistant bacterial infections
HK1244798A1 (en) Combination therapy for treatment of resistant bacterial infections
WO2017203266A1 (en) Combination therapy for treatment of resistant bacterial infections
RU2560846C1 (ru) Фармацевтические композиции, содержащие сулбактам и ингибитор бета-лактамазы
ES2929058T3 (es) Composiciones y procedimientos de uso de combinaciones de fármacos antibacterianos
US20150374673A1 (en) Combination Therapy for the Treatment of Nosocomial Pneumonia
RU2593363C2 (ru) Композиции, включающие антибактериальное средство и тазобактам
US20150224168A1 (en) Combinations with a backbone-cyclized peptide
JP2019116508A (ja) 抗菌剤を含む医薬組成物
CN106794250A (zh) 包含抗菌剂的药物组合物
KR20160130824A (ko) 세페파임 또는 술박탐을 포함하는 제약학적 조성물
Parkins et al. Multidrug-Resistant Pseudomonas aeruginosa in Cystic Fibrosis. Part 2: Management Considerations
US20160175318A1 (en) Compositions comprising antibacterial agent and tazobactam

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)